Cisplatin/Gemcytobine (CG) vs Cisplatin/Gemcytobine/Vinorelbine (CGV) vs Sequential Doublets of Gemcytobine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial

James Metz, MD

University of Pennsylvania Cancer
Ultima Vez Modificado: 12 de mayo del 2001

Share article


Presenter: V. Alberola
Affiliation: Spanish Lung Cancer Group

Background:

    The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens, including a regimen without Cisplatin based therapy.

Materials and Methods:

  • This study included patients with stage IIIb and IV NSCLC.
  • Most patients were has ECOG performance status 0 or 1.
  • Patients were randomized to receive CG (n=166) vs CGV (n=176) vs GV/IV (n=175)

Results:

  • anemia and nausea/vomiting were significantly increased in the CGV regimen
  • The median survival, 1 year survival, and time to progression were not significantly different between the arms

Authors' Conclusions

  • The response rate, time to progression, and survival were the same for CG as the addition of a 3rd agent
  • The hematologic toxicity was increased in the Cisplatin containing arms
  • There was no survival differences between the regimens

Clinical/Scientific Implications:

  • The addition of a third agent to a Cisplatin containing regimen was not shown to increase the benefits for patients
  • The experimental arms in this study were not superior to the control are of CG

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen


News
Doublet Chemo Improves Survival in Elderly With NSCLC

Aug 10, 2011 - Despite more toxic effects, doublet chemotherapy with carboplatin and weekly paclitaxel is associated with significantly higher survival benefits than monotheraphy with either vinorelbine or gemcitabine in elderly patients with advanced non-small-cell lung cancer, according to a study published online Aug. 9 in The Lancet.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información